Skip to content

Thomas Knuijver

3 papers in the library · 65 citations · publishing 2016-2024

Papers

Sort Most recent Most cited

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Journal of psychopharmacology (Oxford, England) May 1, 2024 Thomas Knuijver, Rob Ter Heine, Arnt Schellekens et al. 15 citations

Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. The study was performed in 14...

Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Addiction (Abingdon, England) 2022 Thomas Knuijver, Arnt Schellekens, Maarten Belgers et al. 49 citations

Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non-medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as well as other safety concerns. This study aimed to evaluate the cardiac, cerebellar and psychomimetic safety of ibogaine...

Treatment of heroin dependence with ibogaine

European Psychiatry March 1, 2016 Arnt Schellekens, Toon Van Oosteren, Thomas Knuijver et al. 1 citation

Background The use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates....